




CT/AU03/00453



**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**Patent Office  
Canberra**

I, JONNE YABSLEY, TEAM LEADER EXAMINATION SUPPORT AND  
SALES hereby certify that annexed is a true copy of the Provisional specification  
in connection with Application No. 2003901180 for a patent by EIFFEL  
TECHNOLOGIES LIMITED as filed on 12 March 2003.



WITNESS my hand this  
Fifth day of May 2003

**JONNE YABSLEY  
TEAM LEADER EXAMINATION  
SUPPORT AND SALES**

AUSTRALIA

---

*Patents Act 1990*

---

# PROVISIONAL SPECIFICATION

Invention Title:           **Formulation method**

The invention is described in the following statement:

## FORMULATION METHOD

The present invention relates to methods for the formulation of fine particles of products using liquefied gases or dense gases. It has particular but not exclusive application to the precipitation and encapsulation of fine particles from the molten form of the product.

Particulate products are of great interest for pharmaceutical applications, where there is a need to obtain particles of reproducible, preferably small, size and shape within a narrow size range. These physical criteria are important because the bioavailability of some pharmaceuticals is dependant on the size of the particles. Similarly, bioavailability may be adjusted by coatings (ie, encapsulation) or dispersion (eg, in a polymer matrix, particularly biodegradable polymers).

There are a number of dense gas techniques which have been used in the micronisation of particles. The two techniques particularly relevant to the present invention are Rapid Expansion of Supercritical Solutions (RESS) and Particles from Gas Saturated Solutions (PGSS).

The RESS process involves the material of interest being dissolved in a supercritical fluid solvent under pressure, and precipitating the solute by depressurising the solution across a nozzle.

The PGSS process involves applying a dense gas under pressure to a molten material. The dense gas dissolves in the material of interest to form a solute saturated solution, and the resulting liquid phase is sprayed through a nozzle into a vessel of lower pressure, which results in the dense gas being vaporised, leaving behind fine particles of the desired material. A typical apparatus for this process is illustrated schematically in Figure 1 and described in more detail below. The PGSS process is discussed by Kerč *et al* in *International Journal of Pharmaceuticals*, Vol 182, 1999, 33-39. Since the PGSS process involves first heating the material of interest to its melting point, it is therefore limited to materials which do not thermally degrade below their melting point (ie are not thermally labile). However, as some materials experience a melting point

depression in the presence of a dense gas, they may be used in the PGSS process if the dense gas depresses their melting point below the thermal degradation point. Of course, with some substances, these temperature points are not precise especially where the substance exists in different morphologies.

5 Thus, the PGSS process has been found to have limited applications.

Another disadvantage of the PGSS process is that the viscosity of the solution being sprayed, while less than the viscosity of the molten solute, is still at a level that can cause the nozzle to block.

One known formulation method (which may be used, for example, for  
10 delayed release formulations) is to spray a molten pharmaceutical (or material of interest) into a solution of a sustained release compound (such as stearate) at increased temperature and pressure. This results in the newly formed particles of the pharmaceutical being coated in the stearate (or other similar compound) for  
15 applications is restricted to the few pharmaceutical substances known to melt without decomposing.

Co-formulation of pharmaceuticals has also been proposed for increased efficacy or new applications. These may however be difficult to prepare, particularly if melting a compound so as to mix it with another partly decomposes  
20 it.

In attempting to overcome some of those difficulties and limitations, it has surprisingly been found that some compounds exhibit a melting point depression when exposed to a dense gas, which permits use of a dense gas process with such compounds. This process can be used with substances otherwise  
25 considered unsuitable given their melting point under normal conditions.

### **Summary of one form of the invention**

This invention is directed to substances whose melting point is depressed in the presence of a liquefied gas or a dense gas.

In one embodiment of the invention, there is provided a method for manipulating or formulating a substance comprising contacting the substance with liquefied gas or dense gas to melt the substance, subjecting the molten substance to a flow of the liquefied gas or dense gas to form a solution of at least a part of the substance and the liquefied or dense gas, and then spraying the solution into a vessel of lower pressure to form particles of the substance.

In another embodiment of the invention, there is provided micron-sized or nano-sized particles of the substance prepared by this method.

Preferably, the method is conducted in a sealed chamber containing the liquefied gas or dense gas.

Preferably, the liquefied gas or dense gas is CO<sub>2</sub>. Preferably, the substance is a pharmaceutical or biological compound. Examples include cyclosporine. Usually the substance will be solid at atmospheric pressure and temperature.

The term ("PDGIMS") is used to represent the method of the present invention, and stands for Precipitation from Dense Gas Induced Molten Solutions.

In one embodiment, the first contacting step is conducted at relatively constant elevated temperature or pressure. However, the temperature must be selected so as not to exceed the thermal degradation temperature where the substance is thermally labile.

The invention has particular advantage where the substance undergoes degradation or decomposition at temperatures between its lowered melting point and up to about its melting point at atmospheric pressure. This is because the substance can be melted with reduced degradation or decomposition.

In another embodiment of the invention, there is provided micron-sized or nano-sized particles of the material of interest prepared by a method comprising contacting the substance with liquefied gas or dense gas to melt the substance, subjecting the molten substance to a flow of the liquefied gas or dense gas to form

a solution of at least a part of the substance and the liquefied gas or dense gas, and then spraying the solution into a vessel of lower pressure to form particles of the substance.

In another embodiment of the invention, there is provided an apparatus for  
5 performing a PDGIMS method comprising:

a pressure chamber having an inlet and an outlet, the outlet being above the inlet;

first conduit means connected to the inlet; and

second conduit means extending from the outlet to a depressurisation point.

10 Preferably the depressurisation point is a nozzle.

Preferably there is further provided a third or "bypass" conduit means extending from adjacent the downstream end of the first conduit means to the nozzle. The flow of fluid through the conduit means will generally be controlled by valves.

15 Preferably, the apparatus upstream of the nozzle is maintained at a constant temperature, eg by being contained within a water bath.

In use of the apparatus according to the invention, the first conduit means connects a source of the liquefied gas or dense gas to the inlet, such as a gas bottle. The substance is pre-loaded into the pressure chamber adjacent the inlet.  
20 The gas is then permitted to enter the pressure chamber through the inlet and pressurise the chamber as the second and third conduit means are closed.

The temperature of the system and pressure of the chamber are selected and then monitored during the process such that the substance melts at its depressed melting point and then is left to equilibrate. Having formed a  
25 homogenous solution of substance/gas, the system is pressurised by opening the third conduit means. Gas can thus flow from its source, past the inlet to the depressurisation point to pressurise the system. Once pressurised, the second conduit means is opened, and the third conduit means partly or wholly closed, so

as to force the solution from the pressure chamber, through the outlet, along the second conduit means to the depressurisation point/nozzle, where the solution expands to precipitate fine particles.

Flow rates are adjusted, as appreciated by one skilled in the art, to optimise  
5 the particle formation.

In another embodiment of the invention, the solution is formed continuously so that the PDGIMS process is continuous rather than batch.

The invention can also be used to encapsulate a material, such as a pharmaceutical substance. In one particular application, where it is desirable to  
10 release one drug before another into a metabolic system, the latter drug may be coated in the former by means of this process. This would be particularly suitable if, for example, the first drug aided absorption or inhibited premature degradation/metabolism of the second, which was the primarily active drug. One proposed example of this application of the invention is paclitaxel coated with  
15 cyclosporine. Combinations of immunosuppressives are also contemplated. Accordingly, in one application of the invention, paclitaxel is coated with molten cyclosporine at temperatures only moderately above atmospheric.

In another embodiment, this method can be used to produce micronised particles of a material which are encapsulated by a polymer. This polymer coating  
20 can be selected to impart various properties to the particles, for example, to enable sustained or delayed release of the encapsulated material. For example, the molten substance under the liquefied gas or dense gas could be depressurised through a nozzle so as to precipitate fine particles of the substance. These can then be coated with known coatings (eg, stearate or polylactides) to  
25 formulate the substance for medical administration. The invention can also enable a compound, particularly a lipophilic compound, to be embedded into a lecithin vesicle by depressurising into an aqueous solution to produce an emulsion.

In addition, the invention may be used to facilitate administration of pharmaceuticals which are themselves difficult to administer, such as

pharmaceuticals having low blood solubility. In place of known techniques whereby micro-emulsions of such pharmaceuticals may be formulated for administration to patients, the invention can be used to coat nano-sized particles of the active ingredient in a compound which facilitates blood solubility and is, itself, biodegradable.

The invention may also be used to formulate micron-sized or nano-sized particles of thermally labile compounds as these can be manufactured using the invention well below the decomposition temperature of the pharmaceutically active substance itself yet still be formed into very small particles. The invention also avoids the polymorphism of crystal structure which often results from known methods (eg, crystallising particles from ethanol). Polymorphism can significantly change the bioavailability of a substance, which in turn may require new regulatory approval. Thus, the ability to formulate a substance by melting it at significantly lower temperatures is significant to avoid decomposition, and the rapid formation of the particles (with greater control over the system compared with known techniques) reducing the likelihood of polymorphic forms of the substance being generated.

Advantages of the present method include:

(i) the method produces solutions of the substance in the liquefied gas or dense gas which are much less viscous than the solution of dense gas in the molten substance produced in the PGSS process. Therefore, PDGIMS results in less blocking of the nozzle used to spray the solution.

(ii) the method can be used for substances that are not suitable for PGSS (eg, PGSS cannot be used for substances that do not have sufficiently low viscosity when molten to be sprayed).

(iii) the method can be conducted without the presence of organic solvents;



(iv) since the materials melt at a lower temperature than normal, the method is suitable for thermally labile compounds and core or coated compounds;

(v) the method is more energy efficient than at least some other dense gas processes, because lower temperatures and/or pressures are used;

5 (vi) the core drug is protected;

(vii) less liquefied gas or dense gas is needed than at least some other dense gas processes, which saves costs.

Without being bound by any particular theory or mode of action, it appears that this melting point depression is caused by the adsorption of the liquefied gas  
10 or dense gas into the solid matrix and the resulting solute-solvent intermolecular interactions. The liquefied gas or dense gas therefore effectively dissolves in the liquefied substance (eg, cyclosporine).

In this specification, the term "dense gas" is used to refer generally to a fluid substantially near or above its critical pressure ( $P_c$ ) and temperature ( $T_c$ ). For  
15 practical purposes, the pressure of the fluid is usually in the range  $(0.9-1.2)P_c$  and its temperature  $(0.9-1.2)T_c$ , but these are examples of typical ranges, not limiting examples. The terms "dense gas", "dense fluid" and "expanded fluid" are used synonymously in this specification.

The term "liquefied gas" is used in contradistinction to "dense gas" or  
20 "expanded fluid" to mean a subcritical gas in the liquid phase as a result of elevated pressure at a given temperature.

It will be understood that the term "comprises" (or its grammatical variants) as used in this specification is equivalent to the term "includes" and should not be taken as excluding the presence of other elements of features.

## Brief Description of the Drawings

Figure 1 shows schematically the apparatus used to perform PGSS.

Figure 2 shows schematically the apparatus used to perform the method of the present invention (PDGIMS).

5        Figure 3 shows a pressure-temperature diagram for the cyclosporine-CO<sub>2</sub> system.

Figure 4 is a diagram showing the solubility of cyclosporine at various pressures.

10        Figure 5 shows a Scanning Electron Micrograph (SEM) image of a sample of cyclosporine; (a) before processing using the method of the present invention; (b) after being processed using the method of this invention at 25°C and 160 bar with a 10mm long, 50 micron diameter nozzle.

15        Figure 6 shows an SEM image of cyclosporine processed according to the method of the invention at 45°C and 200 bar with a 10mm long, 50 micron diameter nozzle.

Figure 7 shows an SEM image of cyclosporine processed at 25°C and 170 bar.

20        Figure 8 shows an SEM image of cyclosporine processed according to the method of the invention at 25°C and 200 bar with a 10mm long, 100 micron diameter nozzle.

Figure 9 shows Differential Scanning Calorimetry (DSC) analysis of cyclosporine, unprocessed and processed by PDGIMS.

Figure 10 shows X-ray diffraction (XRD) analysis for cyclosporine.

Figure 11 shows the particle size distribution of cyclosporine, (a)

unprocessed powder, (b) processed by PDGIMS.

Examples of the invention will now be described for greater clarity of the description of the invention. The examples do not limit the scope of the invention described.

## 5 Example 1

Cyclosporine is an immunosuppressant used, for example, to prevent organ rejection in transplant patients, and has a melting point of 120-190°C, depending on its crystalline structure. Cyclosporine A, for example, which is a crystalline form, has a melting point of 148-151°. This melting point can be depressed by  
10 liquefied carbon dioxide, or dense gas carbon dioxide at pressure. For example, when exposed to carbon dioxide at 65 bar pressure (6.5 Mpa) Cyclosporine A melts at 45°C.

A phase behaviour study was conducted to determine the optimum conditions for the melting point depression, the solubilisation of cyclosporine in  
15 CO<sub>2</sub>, and for the particle formation. Figure 3 shows the melting point depression of cyclosporine at various pressures by a pressure-temperature diagram for the cyclosporine-CO<sub>2</sub> system. Figure 4 shows the solubility of cyclosporine at various pressures. The solubility of cyclosporine in liquefied or dense gas CO<sub>2</sub> is high, and its solubility increased as the pressure of the system was changed from 100 to  
20 180 bar.

The phase observation study of the solute-CO<sub>2</sub> system was carried out using a static technique. A glass tube (i.d. = 5.8 mm) loaded with the solute cyclosporine was placed inside the view cell (Jerguson sight gauge series No. 32). The system was then immersed in the constant temperature water bath. Prior to  
25 commencing experiments, the system was purged with low pressure CO<sub>2</sub> in order to remove moisture and air. Carbon dioxide was gradually fed into the view cell at 3 bar increments. The system was isolated and equilibrated for at least 10 minutes after each increase in pressure in order to observe any phase transition of the

solute.

The melting point of cyclosporine was depressed when contacted with CO<sub>2</sub> at 45°C and 65 bar. The normal melting point of cyclosporine is a function of its crystal structure and varies between 120°C and 190°C. The pressure temperature  
5 diagram for the cyclosporine-CO<sub>2</sub> system is presented in Figure 3. As the data in Figure 3 shows, upon increasing the CO<sub>2</sub> pressure, the temperature at which cyclosporine melted increased, but the melting point was still well below the usual melting point.

The solubility of cyclosporine in liquefied or dense gas CO<sub>2</sub> was high. The  
10 solubility of cyclosporine increased as the pressure of the system was changed from 100 to 180 bar (Figure 4). The degree of solubility was slightly increased when the temperature increased from subcritical (25°C) to supercritical (45°C) conditions. Thus, it can be seen that, due to the considerable solubility of cyclosporine in CO<sub>2</sub> and melting point depression behaviour, PDGIMS is an  
15 efficient method for micronisation.

## Example 2

A schematic diagram of the PDGIMS rig used in the method of this invention is shown in Figure 2. Cyclosporine is packed into the Jerguson view cell, 1, being a pressure chamber, with glass wool. The purpose of the glass wool  
20 is to ensure that the molten cyclosporine remains in the view cell, 1. The carbon dioxide can be in supercritical state, a near critical state, or in a liquid state (eg 25°C and 60 bar). The cell is then placed in the water bath, 2, heated by the thermostat heater, 3, to keep the temperature constant at 25°C. Carbon dioxide is introduced into the system via line A, to the bottom of the view cell, 1. The  
25 pressure in the system is controlled by a high pressure syringe pump, 4. As the carbon dioxide pressure increases, the cyclosporine eventually melts (as can be seen from Figure 3, at 25°C, the minimum pressure required to melt cyclosporine is 53°C. and at pressures above this value, the cyclosporine will be molten). The molten cyclosporine was left isolated in the water bath, 2, for at least two hours to

equilibrate before further processing. It may be, however, that the equilibration does not require 2 hours. Line C is a bypass line, which is used to pressurise the nozzle, 5, and for cleaning the nozzle at the end of a run. After Line C and the nozzle have been brought to the operating pressure (the nozzle itself providing sufficient resistance to enable pressurisation), the ball valve, 6 on Line C is used to pressurise the nozzle, 5 (thus avoiding a pressure drop and particle formation before the nozzle, which can cause the nozzle to block.) After the nozzle, 5 is pressurised, the ball valve (7) on Line B is opened, allowing a flow of carbon dioxide through the molten cyclosporine. The gas/cyclosporine mixture is then sprayed into the expansion chamber, 8 (via filter, 9), where particles are formed. A filter, 10 is used to trap all particles within the expansion chamber, 8, and the carbon dioxide is vented from the system through outlet, 11. At the end of the run, ball valve, 7 on line B is closed, and ball valve, 6 on line C is opened, allowing a flow of carbon dioxide through the nozzle, clearing any blockages or material remaining in the system.

One way in which this configuration differs from the configuration of typical PGSS rigs is that the liquefied gas or dense gas is forced from the bottom of the Jerguson view cell to the top. In most PGSS rigs, the gas is fed from the top of the view cell. The purpose of this change in the configuration, is to deliberately keep the liquefied gas or dense gas solution below saturation. This assists in avoiding blockages in the 50 micron nozzle.

The unprocessed cyclosporine contained large irregular crystals with particles in the range of 100  $\mu\text{m}$  (Figure 5(a)). The particles produced by the PDGIMS process at 25°C and 160 bar were on average 5  $\mu\text{m}$  microsphere particles (Figure 5(b)). Other examples of particles produced by the PDGIMS process are shown in Figure 6 (45°C, 200 bar and 50  $\mu\text{m}$  nozzle), Figure 7 (25°C and 170 bar) and Figure 8 (25°C, 200 bar and 100  $\mu\text{m}$  nozzle).

Cyclosporine produced by this technique showed a significant loss of crystallinity. Only the amorphous form of cyclosporine is present after processing. The loss of crystallinity is confirmed by DSC results (shown in Figure 9) where the crystalline peak (at about 120°C) is entirely absent after processing.

**Example 3**

The parameters of the melting point depression observed for cyclosporine were then analysed as follows. The melting point of the drug decreased from 120°C to 25°C, 35°C, 40°C and 50°C when pressurised with CO<sub>2</sub> at 53, 58, 60 and 77 bar, respectively. Micronisation of the cyclosporine by PDGIMS is thus efficient due to the significant drop in melting point at relatively moderate pressures.

The following conditions were maintained during the process:

*post-expansion pressure:* maintained below 3 bar with a pressure relief valve;

*post expansion temperature:* room temperature;

*particle collection device:* particles are collected in a perspex expansion chamber, or a Whitey Chamber. No change in particle morphology or size was observed with the change in particle collection device. The carbon dioxide, in a gas form, leaves the particle collection device via an outlet line. Between the particle collection device and the outlet line is a 0.5 µm filter, which will let particles smaller than 0.5 µm past. Significant amounts of powder were seen in the outlet line after the filter, which was one measure of the size of the particles formed. These particles must be smaller than 0.5 µm to be able to pass the filter.

In the method of the invention, the following parameters can be varied:

*pre-expansion pressure:* between 60 and 200 bar – the solubility of cyclosporine increases as the pressure increases;

*pre-expansion temperature:* 25°C, 40°C and 45°C – no change in particle morphology or solubility of cyclosporine in carbon dioxide is observed with the change of temperature;

*nozzle size:* 50  $\mu\text{m}$  internal diameter and 100  $\mu\text{m}$  internal diameter – the nozzle geometry influences the fluid flow characteristics, the pressure drop along the expansion pathway, and the atomization of the solution. It was found that the nozzle dimension possessed a significant effect on the particle size of the cyclosporine processed by PDGIMS. As can be seen in Figure 8, the particles produced from a 100  $\mu\text{m}$  nozzle were porous and significantly larger than the ones precipitated from a 50  $\mu\text{m}$  nozzle (see Figure 5(b) and 6). Porous structure particles may improve the dissolution rate of the poorly soluble cyclosporine. Thus, increasing the nozzle diameter results in the generation of larger particles. Without being bound by any theory or mode of action, it is believed that this is due to a decrease in pressure drop and density of the fluid at the exit of the nozzle.

Further, again without wishing to be bound by any specific modality of operation, it is believed that the porous structure that was observed in the microspheres might be caused by diffusion of carbon dioxide from the microspheres during the expansion stage.

As shown in Figure 6, the particle size of cyclosporine was not significantly influenced by the pressure and temperature of the system (cf Figure 5(b) – particles produced at 25°C and 160 bar). However, the PDGIMS process was more efficient (ie, a greater yield of product) at high pressures, such as 200 bar, and temperatures such as 45°C.

The degree of crystallinity and polymorphic form of the cyclosporine was examined by x-ray diffraction (XRD) and differential scanning calorimetry (DSC). The results obtained from XRD analysis shown in Figure 10 indicate that the original powder was in crystalline form. The DSC results presented in Figure 9 indicate that the unprocessed crystals of cyclosporine had a melting point of 120°C. Both XRD and DSC confirmed that the cyclosporine powder processed by PDGIMS has no peak at regions characteristic of the existence of crystal forms of the cyclosporine, hence the product must be in amorphous form.

The particle size distribution of the cyclosporine powder was measured by laser diffraction (Master Size, Malvern Instruments, UK). As demonstrated in

Figure 11, which shows the particle size distribution of cyclosporine (a) unprocessed, and (b) processed by PDGIMS, the average particle size and particle size distribution of the cyclosporine processed by PDGIMS was dramatically decreased.

- 5           The trend that was observed in cyclosporine-CO<sub>2</sub> is common for systems where the solid is a heavy and low volatile compound with a critical point far from the critical point of the dense gas.

#### Example 4

- 10           Drugs which may be used in combination with cyclosporine include Basiliximab, Tacrolimus, Docetaxel. There is evidence (ref: *J Clin Oncol* 2001 Feb 15; 19(4): 1160-6) that the bioavailability of docetaxel is strongly enhanced by coadministration of cyclosporine. The invention enables the encapsulation of a compound such as these with cyclosporine.

- 15           In an alternative embodiment, cyclosporine may itself be coated, such as by polycaprolactone into nanoparticles. This has been shown to improve the oral bioavailability of cyclosporine and its uptake by lymphocytes, without a corresponding increase in immunosuppression and adverse effects.

- 20           Cyclosporine can also be incorporated into lecithin vesicles, as cyclosporine is lipophilic. It is first melted under dense gas and then mixed with a phospholipid, such as lecithin. A surfactant, preferably a non-ionic surfactant (eg, polysorbate, TWEENS, SPANs, polyethoxylated castor oil, etc) may also be added at this point. The mixture is then depressurised into an aqueous solution (rather than into air as in the previous examples). The resulting solution will be an emulsion containing cyclosporine in small vesicles or micelles. This is an efficient way of generating a  
25           cyclosporine (or other lipophilic compound) aqueous emulsion, without the cyclosporine decomposing.

Improved bioavailability of cyclosporine has also been shown by forming microspheres containing cyclosporine and sodium lauryl sulphate ("SLS"). In




particular, cyclosporine, SLS and dextrin in the ratio of 1:3:1 has been found very effective. The invention can utilise the decreased melting point of cyclosporine in the presence of dense CO<sub>2</sub> to create such spheres by then mixing it with the SLS and dextrin in the required ratios.

- 5        The invention is equally applicable to cyclosporine derivatives, such as valspodar.

- 10       It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.


Eiffel Technologies Limited  
By its Registered Patent Attorneys  
Freehills Carter Smith Beadle

12 March 2003




**Figure 1**


**(prior art)**




**Figure 2**




**Figure 3**



**Figure 4**




(a)





(b)

**Figure 5**



**Figure 6**




**Figure 7**






**Figure 8**




**Figure 9**



**Figure 10**

(a)



(b)




Figure 11